Stocks TelegraphStocks Telegraph
Stock Ideas

AMLX Financial Statements and Analysis

NASDAQ : AMLX

Amylyx Pharmaceuticals, Inc.

$3.70
0.08+2.21%
Open: 9:45 AM
42.78
C+ESG ScoreESG Rating

AMLX FINANCIAL STATEMENTS

An instrumental part of fundamental analysis is measuring key indicators of an asset, which are the factors that can influence its value and price. However, sometimes investors show more interest in financial statements with other factors to determine whether investing in that company is the right decision. Financial statements of a company include:

  • Balance Sheet
  • Income Statement
  • Cash Flow Statement

AMLX Income Statement

A company's income statement helps investors and business owners determine whether the company is profitable or losing money. Profitability is a key factor investors consider before investing in a stock. Income statements provide them with information about a company's profitability over time. The statement also enables them to observe trends in company spending and earnings since it breaks down individual costs and revenues. Income statements also provide details on where a company's money is going when it isn't profitable or its profits fluctuate.

Date2024-09-302024-06-302024-03-312023-12-312023-09-30
reported currencyUSDUSDUSDUSDUSD
calendar year20242024202420232023
periodQ3Q2Q1Q4Q3
revenue416.00K-1.023M88.643M108.449M102.693M
cost of revenue809.00K7.626M116.721M9.36M5.218M
gross profit-393.00K-8.649M-28.078M99.089M97.475M
gross profit ratio-0.9458.455-0.3170.9140.949
research and development expenses21.237M23.139M36.293M44.914M30.037M
general and administrative expenses0057.759M42.741M48.718M
selling and marketing expenses0009.50M0
selling general and administrative expenses17.828M21.647M57.759M52.241M48.718M
other expenses36.203M-483.00K-747.00K171.00K-488.00K
operating expenses75.268M44.786M94.052M97.155M78.755M
cost and expenses76.077M52.412M210.773M106.515M83.973M
interest income3.098M4.069M4.326M4.371M4.179M
interest expense00000
depreciation and amortization221.00K208.00K315.00K301.00K302.00K
ebitda-39.237M-53.227M-121.815M2.235M19.022M
ebitda ratio-94.3252.03-1.3740.0210.185
operating income-75.661M-53.435M-122.13M1.934M18.72M
operating income ratio-181.87752.234-1.3780.0180.182
total other income expenses net2.957M-19.265M3.579M171.00K-488.00K
income before tax-72.704M-72.70M-118.551M6.476M22.411M
income before tax ratio-174.76971.066-1.3370.060.218
income tax expense00242.00K1.745M1.518M
net income-72.704M-72.70M-118.793M4.731M20.893M
net income ratio-174.76971.066-1.340.0440.203
eps-1.07-1.07-1.750.070.31
eps diluted-1.07-1.07-1.750.0680.30
weighted average shs out68.091M68.025M67.854M67.415M67.415M
weighted average shs out dil68.091M68.025M67.854M69.196M69.749M
Graph

AMLX Balance Sheet

Balance sheet summarizes a company's financials and can be used as a basis by investors to determine the value of a company. It shows the value of the stock, as well as the assets and liabilities of the company. A company's balance sheet displays how its assets are put to use and how those assets are financed, based on the liabilities section. Both investors and analysts analyze a company's balance sheet to determine how it allocates its resources.

Date2024-09-302024-06-302024-03-312023-12-312023-09-30
reported currencyUSDUSDUSDUSDUSD
calendar year20242024202420232023
periodQ3Q2Q1Q4Q3
cash and cash equivalents71.839M74.999M170.552M170.201M135.258M
short term investments162.556M234.813M202.741M201.161M219.787M
cash and short term investments234.395M309.812M373.293M371.362M355.045M
net receivables1.731M4.091M20.351M40.05M29.453M
inventory001.0038.323M32.374M
other current assets9.137M12.819M16.89M14.931M17.238M
total current assets245.263M326.722M410.534M464.666M434.11M
property plant equipment net3.527M4.242M5.711M6.411M6.95M
goodwill00000
intangible assets00000
goodwill and intangible assets00000
long term investments0719.00K719.00K719.00K25.048M
tax assets00000
other non current assets1.923M478.999K493.00K45.658M475.999K
total non current assets5.45M5.44M6.923M52.788M32.474M
other assets01.00001.00
total assets250.713M332.162M417.457M517.454M466.584M
account payables1.487M4.955M21.453M22.061M6.371M
short term debt1.972M2.369M4.624M2.257M2.201M
tax payables00000
deferred revenue00000
other current liabilities50.456M62.757M65.562M57.724M37.045M
total current liabilities53.915M70.081M91.639M82.042M45.617M
long term debt595.00K772.00K1.382M1.98M2.567M
deferred revenue non current00000
deferred tax liabilities non current00000
other non current liabilities00000
total non current liabilities595.00K771.999K1.382M1.98M2.567M
other liabilities01.00000
capital lease obligations2.567M772.00K1.382M4.237M4.768M
total liabilities54.51M70.853M93.021M84.022M48.184M
preferred stock0000466.584M
common stock7.00K7.00K7.00K7.00K7.00K
retained earnings-569.146M-496.442M-423.742M-304.949M-309.68M
accumulated other comprehensive income loss641.00K-97.00K-77.00K197.00K-151.00K
other total stockholders equity764.701M757.841M748.248M738.177M261.64M
total stockholders equity196.203M261.309M324.436M433.432M418.40M
total equity196.203M261.309M324.436M433.432M418.40M
total liabilities and stockholders equity250.713M332.162M417.457M517.454M466.584M
minority interest00000
total investments162.556M235.532M203.46M201.161M219.787M
total debt2.567M3.141M3.694M4.237M4.768M
net debt-69.272M-71.858M-166.858M-165.964M-130.49M
Graph

AMLX Cash Flow

A cash flow statement is regarded as a valuable indicator of profitability and the long-term outlook for a company. It assists the company in evaluating whether it has sufficient funds to cover its expenses. Essentially, a cash flow statement represents an organization's financial health. The cash flow statement, which measures the business's ability to operate in the short as well as long term, is broken down into operating, investing, and financing activities.

Date2024-09-302024-06-302024-03-312023-12-312023-09-30
reported currencyUSDUSDUSDUSDUSD
calendar year20242024202420232023
periodQ3Q2Q1Q4Q3
deferred income tax00000
stock based compensation6.803M9.57M9.924M9.534M10.176M
change in working capital8.531M-8.695M164.00K1.557M-34.058M
accounts receivables2.361M16.26M19.698M-10.697M4.12M
inventory00-9.253M-26.481M-14.012M
accounts payables-3.487M-16.435M-652.00K15.82M-18.393M
other working capital18.149M-8.52M-9.629M22.915M-5.773M
other non cash items15.579M15.198M108.662M-2.572M-2.482M
net cash provided by operating activities-41.57M-66.58M-489.00K13.551M-5.169M
investments in property plant and equipment19.00K-89.00K-67.00K-356.00K-357.00K
acquisitions net0000107.731M
purchases of investments0-158.872M-73.114M-126.639M-164.431M
sales maturities of investments75.00M130.00M74.00M147.92M56.70M
other investing activites-36.203M-28.872M886.00K0-107.731M
net cash used for investing activites38.816M-28.961M819.00K20.925M-108.088M
debt repayment00000
common stock issued-1.493M47.00K1.446M347.00K984.00K
common stock repurchased1.335M-20.00K-1.315M0-95.00K
dividends paid00000
other financing activites238.00K-20.00K-1.315M-117.00K-95.00K
net cash used provided by financing activities80.00K27.00K131.00K230.00K889.00K
effect of forex changes on cash236.00K-39.00K-110.00K237.00K-134.00K
net change in cash-1.719M-95.553M351.00K34.943M-112.502M
cash at end of period73.28M74.999M170.552M170.92M135.977M
cash at beginning of period74.999M170.552M170.201M135.977M248.479M
operating cashflow-41.57M-66.58M-489.00K13.551M-5.169M
capital expenditure19.00K-89.00K-67.00K-356.00K-357.00K
free cash flow-41.551M-66.669M-556.00K13.195M-5.526M
Graph

Frequently Asked Questions

How did Amylyx Pharmaceuticals, Inc. do last quarter? What was its Total Revenue and Cost of Revenue?

A company's Total Revenue reveals how much money it generates before any expenses or deductions are made. As a result, this metric informs investors/stakeholders how much money the business makes. Tracking and understanding it is essential for evaluating a company's growth. As opposed to revenue, Cost of Revenue is any expenses a business incur to generate revenue. There can be high revenue in a business, but if the costs are high, it won't make a profit and will go out of business when money runs out. Therefore, AMLX generated $416.00K in revenue last quarter, while its costs came in at $809.00K.

Last quarter, how much Gross Profit did Amylyx Pharmaceuticals, Inc. report?

A business's Gross Profit is a key indicator of its profitability and financial performance. In other words, it reflects how efficiently a business uses labor, raw materials, and other resources. Amylyx Pharmaceuticals, Inc. reported a -$393.00K Gross Profit for the quarter ended Sep 30, 2024.

Have AMLX's Total Operating Expenses and Operating Income been favorable recently?

Operational Expenses represent the costs a company must incur to generate revenue, which is the ultimate goal of a business, whereas Operating Income shows the revenue left after operational direct and indirect costs have been deducted. AMLX incurred $75.27M worth of Operating Expenses, while it generated -$75.66M worth of Operating Income.

How much Net Income has AMLX posted recently?

The Net Income of a company is one of the factors investors consider when investing in the company. According to recent earnings report from Amylyx Pharmaceuticals, Inc., the company generated -$72.70M in Net Income. When a company has a history of consistent net income, investors are more likely to invest in it since they know they will get a return.

At the end of the last quarter, how much Cash and Equivalents did Amylyx Pharmaceuticals, Inc. have?

The amount of Cash and Cash Equivalents is an effective indicator of the financial strength and well-being of a company. An excess cash situation occurs when a company has more cash and cash equivalents than it needs for operating activities. The amount of Cash and Cash Equivalents available to Amylyx Pharmaceuticals, Inc. as of the end of the last quarter was $71.84M.

What are AMLX's Total Net Receivables for the last quarter?

Total Net Receivables are a company's outstanding debts to its customers. Therefore, it refers to the amount that a company expects to collect from its customers. The higher a company's net receivables are, the more confident it is that it can collect money from its debtors. As of the end of the last quarter, AMLX had Total Net Receivables of $1.73M.

In terms of Total Assets and Current Assets, where did Amylyx Pharmaceuticals, Inc. stand at?

An asset with an economic value within a year is considered a current asset. Total assets, however, also include long-term fixed assets, intangible assets, and other non-current assets. The current Assets of AMLX were $245.26M, while the Total Assets stand at $250.71M.

As of the last quarter, how much Total Debt did Amylyx Pharmaceuticals, Inc. have?

The total debt of a business refers to how much it borrows. A company's current and long-term liabilities are added together to calculate its Total Debt. A debt ratio may be taken into account on a balance sheet by financial lenders, investors, and business leaders when making informed decisions about future loans or investments. The total amount of AMLX's debt was $2.57M at the end of the last quarter.

What were AMLX's Total Liabilities during the last reported quarter?

A company's total liabilities are the sum of all debts it is liable for, including any off-balance shee liabilities it may incur. This can be calculated by adding up all short-term and long-term liabilities. In its last quarter, AMLX reported total liabilities of $54.51M.

How much did AMLX's Working Capital change over the last quarter?

Working Capital Change for AMLX was $8.53M over the last quarter. Working Capital Change refers to the difference between net working capital amounts at the end of one accounting period and the end of another. It tells investors/stakeholders how much the company's cash flow will differ from its Net Income (i.e., after-tax profits). More powerful companies often have positive Change in Working Capital numbers as they have increased control over collecting cash from customers and delaying payments to suppliers.

AMLX generated how much cash from operating activities?

An operating cash flow statement usually contains cash from operating activities in the first section. An organization's cash from operating activities refers to the money it takes in and takes out as a result of its regular business operations. AMLX generated -$41.57M of Cash from Operating Activities during its recently reported quarter.

What was AMLX's latest reported Net Change in Cash?

An increase or decrease in cash and cash equivalent balances within a specified period is considered the net change in cash in a cash flow statement. Furthermore, it takes into account cash changes as a result of investments, financing, and operating activities. AMLX reported a -$1.72M Net Change in Cash in the most recent quarter.

logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph